D
Deborah DeHertogh
Researcher at Bristol-Myers Squibb
Publications - 12
Citations - 3330
Deborah DeHertogh is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Entecavir & Viral load. The author has an hindex of 8, co-authored 12 publications receiving 3225 citations. Previous affiliations of Deborah DeHertogh include University of Connecticut.
Papers
More filters
Journal ArticleDOI
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B
Ting-Tsung Chang,Robert G. Gish,Robert A. de Man,Adrián Gadano,Jose D. Sollano,You Chen Chao,Anna S. Lok,Kwang Hyub Han,Zachary Goodman,J. Zhu,Anne Cross,Deborah DeHertogh,R B Wilber,Richard J. Colonno,David Apelian +14 more
TL;DR: Among patients with HBeAg-positive chronic hepatitis B, the rates of histologic, virologic, and biochemical improvement are significantly higher with entecavir than with lamivudine, and the safety profile of the two agents is similar.
Journal ArticleDOI
Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B
Ching-Lung Lai,Daniel Shouval,Anna S. Lok,Ting-Tsung Chang,Hugo Cheinquer,Zachary Goodman,Deborah DeHertogh,R B Wilber,Richard C. Zink,Anne Cross,Richard J. Colonno,Lori Fernandes +11 more
TL;DR: Among patients with HBeAg-negative chronic hepatitis B who had not previously been treated with a nucleoside analogue, the rates of histologic improvement, virologic response, and normalization of alanine aminotransferase levels were significantly higher at 48 weeks with entecavir than with lamivudine.
Journal ArticleDOI
Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection
Ching-Lung Lai,Mohamed Rosmawati,Judy Lao,Hans Van Vlierberghe,Frank H. Anderson,Neal Thomas,Deborah DeHertogh +6 more
TL;DR: This study showed that entecavir has potent antiviral activity against HBV at 0.1- mg/day and 0.5-mg/day doses, both of which were superior to lamivudine in chronically infected HBV patients.
Journal ArticleDOI
Prednisone management of granulomatous mastitis.
TL;DR: Ganulomatous mastitis, a lesion that clinically mimics carcinoma, was definitively described in 19721 and is characterized by breast masses that histologically consist of noncaseating granulomas a...
Journal ArticleDOI
Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection.
Robert A. de Man,L. M. M. Wolters,Frederik Nevens,David Chua,Morris Sherman,Cing L. Lai,Adrián Gadano,Youngmee Lee,Fransesco Mazzotta,Neil Thomas,Deborah DeHertogh +10 more
TL;DR: In this 28‐day study of entecavir a pronounced decrease of HBV DNA was observed and there were no significant side effects in entecvir patients in comparison with placebo‐treated patients.